Artículos por temáticas

Transient psychosis due to caregiver burden in a patient caring for severely demented spouses

Zverova M.

Neuro Endocrinol Lett. 2012;33(4):372-4.

Does physical activity reduce risk for Alzheimer's disease through interaction with the stress neuroendocrine system?

Tortosa-Martínez J, Clow A.

Stress. 2012 May;15(3):243-61. doi: 10.3109/10253890.2011.629323. Epub 2012 Jan 4.

Psychometric evaluation of the Swedish version of the Person-Centered Care Assessment Tool (P-CAT)

Sjögren K, Lindkvist M, Sandman PO, Zingmark K, Edvardsson D.

Int Psychogeriatr. 2012 Mar;24(3):406-15. doi: 10.1017/S104161021100202X. Epub 2011 Nov 1.

Two galantamine titration regimens in patients switched from donepezil

Engedal K, Davis B, Richarz U, Han J, Schäuble B, Andreasen N.

Acta Neurol Scand. 2012 Jul;126(1):37-44. doi: 10.1111/j.1600-0404.2011.01594.x. Epub 2011 Oct 13.

Apolipoprotein E genotype-specific short-term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimer's patients--an open-label trial

Kennelly S, Abdullah L, Kenny RA, Mathura V, Luis CA, Mouzon B, Crawford F, Mullan M, Lawlor B.

Int J Geriatr Psychiatry. 2012 Apr;27(4):415-22. doi: 10.1002/gps.2735. Epub 2011 May 10.

A community-based exercise programme to improve functional ability in people with Alzheimer's disease: a randomized controlled trial

Vreugdenhil A, Cannell J, Davies A, Razay G.

Scand J Caring Sci. 2012 Mar;26(1):12-9. doi: 10.1111/j.1471-6712.2011.00895.x. Epub 2011 May 12.

[Psychotropic medication of elderly patients]

Kumagai R, Iseki E.

Nihon Rinsho. 2012 Jan;70(1):140-4.

Anticholinesterase-induced symptoms improved by pacemaker implantation in patients with Alzheimer's disease: analysis of 6 cases

Osmonov D, Özcan KS, Erdinler I, Altay S, Turkkan C, Yildirim E, Gurkan K.

Am J Alzheimers Dis Other Demen. 2012 Aug;27(5):311-4. doi: 10.1177/1533317512452040.

Impact of transdermal drug delivery on treatment adherence in patients with Alzheimer's disease

Molinuevo JL, Arranz FJ.

Expert Rev Neurother. 2012 Jan;12(1):31-7. doi: 10.1586/ern.11.178.

Cardiac safety of donepezil in elderly patients with Alzheimer disease

Isik AT, Yildiz GB, Bozoglu E, Yay A, Aydemir E.

Intern Med. 2012;51(6):575-8. doi: 10.2169/internalmedicine.51.6671. Epub 2012 Mar 15.

Effects of atorvastatin on cerebral blood flow in middle-aged adults at risk for Alzheimer's disease: a pilot study

Carlsson CM, Xu G, Wen Z, Barnet JH, Blazel HM, Chappell RJ, Stein JH, Asthana S, Sager MA, Alsop DC, Rowley HA, Fain SB, Johnson SC.

Curr Alzheimer Res. 2012 Oct;9(8):990-7. doi: 10.2174/156720512803251075.

The immunology of traumatic brain injury: a prime target for Alzheimer's disease prevention

Giunta B, Obregon D, Velisetty R, Sanberg PR, Borlongan CV, Tan J.

J Neuroinflammation. 2012 Aug 1;9:185. doi: 10.1186/1742-2094-9-185.

Health state values for use in the economic evaluation of treatments for Alzheimer's disease

Shearer J, Green C, Ritchie CW, Zajicek JP.

Drugs Aging. 2012 Jan 1;29(1):31-43. doi: 10.2165/11597380-000000000-00000.

Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer's disease

Francis PT, Parsons CG, Jones RW.

Expert Rev Neurother. 2012 Nov;12(11):1351-65. doi: 10.1586/ern.12.124.

CSF biomarkers for secondary prevention trials: why markers of amyloid deposition and neurodegeneration are both important

Holtzman DM.

Arch Neurol. 2012 Jun;69(6):691-2. doi: 10.1001/archneurol.2012.587.